Bosh sahifaRGLS • NASDAQ
add
Regulus Therapeutics Inc
8,22 $
Seans yopilganidan keyin:(0,12%)-0,010
8,21 $
Yopilgan:6-iyn, 17:42:27 (GMT-4) · USD · NASDAQ · Ogohlantirish
Yopilish kursi
8,10 $
Kunlik diapazon
8,07 $ - 8,28 $
Yillik diapazon
0,83 $ - 8,28 $
Bozor kapitalizatsiyasi
569,10 mln USD
Oʻrtacha hajm
2,38 mln
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | — | — |
Joriy xarajat | 3,72 mln | 33,49% |
Sof foyda | -9,63 mln | -13,76% |
Sof foyda marjasi | — | — |
Har bir ulushga tushum | -0,15 | 48,28% |
EBITDA | -10,45 mln | -19,53% |
Amaldagi soliq stavkasi | — | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 65,37 mln | -32,99% |
Jami aktivlari | 74,83 mln | -34,44% |
Jami passivlari | 5,80 mln | -11,48% |
Umumiy kapital | 69,03 mln | — |
Tarqatilgan aksiyalar | 69,23 mln | — |
Narxi/balansdagi bahosi | 7,79 | — |
Aktivlardan daromad | -33,14% | — |
Kapitaldan daromad | -35,63% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -9,63 mln | -13,76% |
Operatsiyalardan naqd pul | -10,61 mln | -21,40% |
Sarmoyadan naqd pul | 21,50 mln | 127,37% |
Moliyadan naqd pul | 45,00 ming | -99,95% |
Naqd pulning sof oʻzgarishi | 10,93 mln | 87,87% |
Boʻsh pul | -6,34 mln | -1,31% |
Haqida
Regulus Therapeutics Inc. is a clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases. Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals. In April 2025, Novartis announced that it had entered into an agreement to acquire Regulus. Wikipedia
Tashkil etilgan
sen 2007
Sayt
Xodimlar soni
34
